Do analysts prefer TLSA or MDXH?

MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 198.36%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has preferable earnings & valuation, TLSA or MDXH?

Tiziana Life Sciences has higher earnings, but lower revenue than MDxHealth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A MDxHealth $107.88M 0.33 -$33.52M -$0.72 N/A

Is TLSA or MDXH more profitable?

Tiziana Life Sciences has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A MDxHealth -33.46% N/A -24.25%

Does the media refer more to TLSA or MDXH?

In the previous week, Tiziana Life Sciences had 2 more articles in the media than MDxHealth. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 1 mentions for MDxHealth. Tiziana Life Sciences' average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MDxHealth 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MDXH or CNTB?

In the previous week, Connect Biopharma had 2 more articles in the media than MDxHealth. MarketBeat recorded 3 mentions for Connect Biopharma and 1 mentions for MDxHealth. Connect Biopharma's average media sentiment score of 0.13 beat MDxHealth's score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, IMDX or MDXH?

MDxHealth has higher revenue and earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncocyte $4.05M 33.29 -$50.22M -$1.49 N/A MDxHealth $107.88M 0.33 -$33.52M -$0.72 N/A

Is IMDX or MDXH more profitable?

MDxHealth has a net margin of -33.46% compared to Oncocyte's net margin of -2,955.63%. Company Net Margins Return on Equity Return on Assets Oncocyte -2,955.63% N/A -107.52% MDxHealth -33.46% N/A -24.25%

Does the media refer more to IMDX or MDXH?

In the previous week, Oncocyte and Oncocyte both had 1 articles in the media. Oncocyte's average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MDxHealth 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EQ or MDXH more profitable?

Equillium has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -41.15% -38.29% MDxHealth -33.46% N/A -24.25%

Does the media refer more to EQ or MDXH?

In the previous week, Equillium had 1 more articles in the media than MDxHealth. MarketBeat recorded 2 mentions for Equillium and 1 mentions for MDxHealth. Equillium's average media sentiment score of 0.90 beat MDxHealth's score of 0.00 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MDxHealth 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PMN or MDXH?

In the previous week, Promis Neurosciences had 2 more articles in the media than MDxHealth. MarketBeat recorded 3 mentions for Promis Neurosciences and 1 mentions for MDxHealth. Promis Neurosciences' average media sentiment score of 0.34 beat MDxHealth's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MDxHealth 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MDxHealth (MDXH) Competitors

$0.73 +0.02 (+2.28%)

As of 09/3/2026 04:00 PM Eastern

Compare

MDXH vs. TLSA, CNTB, IMDX, EQ, and PMN

Should you buy MDxHealth stock or one of its competitors? MDxHealth's main competitors and comparable companies include Tiziana Life Sciences (TLSA), Connect Biopharma (CNTB), Oncocyte (IMDX), Equillium (EQ), and Promis Neurosciences (PMN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MDxHealth compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 198.36%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Tiziana Life Sciences has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
MDxHealth	-33.46%	N/A	-24.25%

In the previous week, Tiziana Life Sciences had 2 more articles in the media than MDxHealth. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 1 mentions for MDxHealth. Tiziana Life Sciences' average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MDxHealth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tiziana Life Sciences has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Tiziana Life Sciences has higher earnings, but lower revenue than MDxHealth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
MDxHealth	$107.88M	0.33	-$33.52M	-$0.72	N/A

Summary

MDxHealth beats Tiziana Life Sciences on 5 of the 9 factors compared between the two stocks.

How does MDxHealth compare to Connect Biopharma?

MDxHealth (NASDAQ:MDXH) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, Connect Biopharma had 2 more articles in the media than MDxHealth. MarketBeat recorded 3 mentions for Connect Biopharma and 1 mentions for MDxHealth. Connect Biopharma's average media sentiment score of 0.13 beat MDxHealth's score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MDxHealth currently has a consensus price target of $2.17, suggesting a potential upside of 198.36%. Connect Biopharma has a consensus price target of $7.43, suggesting a potential upside of 284.90%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

MDxHealth has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.33	-$33.52M	-$0.72	N/A
Connect Biopharma	$60K	2,025.54	-$55.48M	-$1.19	N/A

MDxHealth has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market.

58.7% of Connect Biopharma shares are held by institutional investors. 1.7% of MDxHealth shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Connect Biopharma has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Connect Biopharma	N/A	-165.41%	-121.58%

Summary

Connect Biopharma beats MDxHealth on 9 of the 16 factors compared between the two stocks.

How does MDxHealth compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

55.4% of Oncocyte shares are held by institutional investors. 2.2% of Oncocyte shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Oncocyte presently has a consensus target price of $10.50, indicating a potential upside of 154.85%. MDxHealth has a consensus target price of $2.17, indicating a potential upside of 198.36%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Oncocyte and Oncocyte both had 1 articles in the media. Oncocyte's average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MDxHealth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MDxHealth has a net margin of -33.46% compared to Oncocyte's net margin of -2,955.63%.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
MDxHealth	-33.46%	N/A	-24.25%

MDxHealth has higher revenue and earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	33.29	-$50.22M	-$1.49	N/A
MDxHealth	$107.88M	0.33	-$33.52M	-$0.72	N/A

Oncocyte has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Summary

MDxHealth beats Oncocyte on 9 of the 13 factors compared between the two stocks.

How does MDxHealth compare to Equillium?

Equillium (NASDAQ:EQ) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Equillium had 1 more articles in the media than MDxHealth. MarketBeat recorded 2 mentions for Equillium and 1 mentions for MDxHealth. Equillium's average media sentiment score of 0.90 beat MDxHealth's score of 0.00 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MDxHealth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Equillium has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
MDxHealth	-33.46%	N/A	-24.25%

Equillium has higher earnings, but lower revenue than MDxHealth. Equillium is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	3.43	-$22.40M	-$0.20	N/A
MDxHealth	$107.88M	0.33	-$33.52M	-$0.72	N/A

Equillium presently has a consensus price target of $7.57, indicating a potential upside of 241.06%. MDxHealth has a consensus price target of $2.17, indicating a potential upside of 198.36%. Given Equillium's stronger consensus rating and higher probable upside, research analysts clearly believe Equillium is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Equillium has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

27.1% of Equillium shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Comparatively, 1.7% of MDxHealth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Equillium beats MDxHealth on 13 of the 17 factors compared between the two stocks.

How does MDxHealth compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

In the previous week, Promis Neurosciences had 2 more articles in the media than MDxHealth. MarketBeat recorded 3 mentions for Promis Neurosciences and 1 mentions for MDxHealth. Promis Neurosciences' average media sentiment score of 0.34 beat MDxHealth's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MDxHealth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Promis Neurosciences has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-143.09%	-109.15%
MDxHealth	-33.46%	N/A	-24.25%

50.1% of Promis Neurosciences shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Promis Neurosciences has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Promis Neurosciences currently has a consensus target price of $34.00, indicating a potential upside of 163.57%. MDxHealth has a consensus target price of $2.17, indicating a potential upside of 198.36%. Given MDxHealth's higher possible upside, analysts plainly believe MDxHealth is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

MDxHealth has higher revenue and earnings than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A
MDxHealth	$107.88M	0.33	-$33.52M	-$0.72	N/A

Summary

MDxHealth beats Promis Neurosciences on 9 of the 16 factors compared between the two stocks.

Get MDxHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXH vs. The Competition

Export

Metric	MDxHealth	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$35.14M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.01	12.66	273.29	25.38
Price / Sales	0.33	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-1.19	16.29	12.89	6.14
Net Income	-$33.52M	-$22.72M	$3.47B	$349.01M
7 Day Performance	0.76%	0.34%	0.60%	-0.27%
1 Month Performance	64.30%	8.52%	5.73%	0.68%
1 Year Performance	-79.43%	52.66%	25.35%	14.84%

MDxHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXH MDxHealth	2.018 of 5 stars	$0.73 +2.3%	$2.17 +198.4%	-79.8%	$35.14M	$107.88M	N/A	300	Gap Up
TLSA Tiziana Life Sciences	1.2334 of 5 stars	$1.11 -3.5%	N/A	-44.3%	$146.35M	N/A	N/A	8	News Coverage Analyst Forecast Gap Up
CNTB Connect Biopharma	3.3988 of 5 stars	$2.45 +6.5%	$7.43 +203.2%	-3.0%	$144.84M	$60K	N/A	110	Gap Up
IMDX Oncocyte	1.7276 of 5 stars	$4.44 +2.8%	$10.50 +136.5%	N/A	$141.37M	$4.05M	N/A	120
EQ Equillium	2.3486 of 5 stars	$2.18 -0.9%	$7.57 +247.3%	+18.7%	$139.50M	$41.10M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXH) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MDxHealth (MDXH) Competitors

MDXH vs. TLSA, CNTB, IMDX, EQ, and PMN

How does MDxHealth compare to Tiziana Life Sciences?

Summary

How does MDxHealth compare to Connect Biopharma?

Summary

How does MDxHealth compare to Oncocyte?

Summary

How does MDxHealth compare to Equillium?

Summary

How does MDxHealth compare to Promis Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH vs. The Competition

MDxHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MDxHealth (MDXH) Competitors

MDXH vs. TLSA, CNTB, IMDX, EQ, and PMN

How does MDxHealth compare to Tiziana Life Sciences?

Do analysts prefer TLSA or MDXH?

Is TLSA or MDXH more profitable?

Does the media refer more to TLSA or MDXH?

Which has more risk & volatility, TLSA or MDXH?

Which has preferable earnings & valuation, TLSA or MDXH?

Summary

How does MDxHealth compare to Connect Biopharma?

Does the media prefer MDXH or CNTB?

Do analysts prefer MDXH or CNTB?

Which has better valuation & earnings, MDXH or CNTB?

Which has more volatility and risk, MDXH or CNTB?

Do insiders and institutionals have more ownership in MDXH or CNTB?

Is MDXH or CNTB more profitable?

Summary

How does MDxHealth compare to Oncocyte?

Do insiders & institutionals have more ownership in IMDX or MDXH?

Do analysts prefer IMDX or MDXH?

Does the media refer more to IMDX or MDXH?

Is IMDX or MDXH more profitable?

Which has stronger valuation & earnings, IMDX or MDXH?

Which has more volatility & risk, IMDX or MDXH?

Summary

How does MDxHealth compare to Equillium?

Does the media refer more to EQ or MDXH?

Is EQ or MDXH more profitable?

Which has better valuation and earnings, EQ or MDXH?

Do analysts rate EQ or MDXH?

Which has more risk and volatility, EQ or MDXH?

Do institutionals and insiders have more ownership in EQ or MDXH?

Summary

How does MDxHealth compare to Promis Neurosciences?

Does the media refer more to PMN or MDXH?

Is PMN or MDXH more profitable?

Do institutionals & insiders have more ownership in PMN or MDXH?

Which has more volatility and risk, PMN or MDXH?

Do analysts rate PMN or MDXH?

Which has higher earnings & valuation, PMN or MDXH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH vs. The Competition

MDxHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools